Develop proofs-of-concept for two novel COVID-19 drugs to begin clinical trials (Jeffrey Glenn)

Glenn is preparing two potential COVID-19 drugs for clinical trials: a lipid kinase inhibitor that could be used to combat COVID-19 and other viruses, and a locked nucleic acid, similar to one that he has successfully developed to target every known strain of the flu and that could potentially be used during any flu pandemic. Both of these drugs could treat multiple viruses and strains, have high barriers to resistance, and, in some cases, could be used in nonviral applications. Stanford Office of Technology Licensing info@otlmail.stanford.edu. 650-723-0651